Holen Sie sich die Stockscreener-App
0.4705
6.99%
-0.0332
Schlusskurs vom Vortag:
$0.5037
Offen:
$0.4804
24-Stunden-Volumen:
828.35K
Relative Volume:
0.25
Marktkapitalisierung:
$10.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.51M
KGV:
-0.3478
EPS:
-1.3528
Netto-Cashflow:
$-15.68M
1W Leistung:
-66.05%
1M Leistung:
-50.68%
6M Leistung:
-79.18%
1J Leistung:
-82.05%
1-Tages-Spanne:
$0.4652
$0.4804
1-Wochen-Bereich:
$0.37
$1.14
52-Wochen-Spanne:
$0.37
$8.94
Medicus Pharma Ltd Stock (MDCX) Company Profile
Firmenname
Medicus Pharma Ltd
Sektor
Telefon
610-540-7515
Adresse
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
0.47 | 11.63M | 0 | -16.51M | -15.68M | -1.3528 |
|
LLY
Lilly Eli Co
|
994.30 | 894.20B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
242.27 | 587.32B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
226.38 | 401.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
192.99 | 302.39B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
155.67 | 308.34B | 54.72B | 14.02B | 15.32B | 7.1855 |
Medicus Pharma Ltd Aktie (MDCX) Neueste Nachrichten
Medicus Pharma on Bloomberg World - The Arizona Republic
Medicus Pharma Reports Phase 2 Results for Basal Cell Carcinoma Therapy - MyChesCo
Medicus Pharma to spotlight AI-driven drug development at Longwood Miami CEO Forum - Proactive financial news
Medicus Pharma to Spotlight AI-Driven Drug Development at Longwood Miami CEO Forum - TipRanks
Medicus Pharma Ltd. To Participate In The Longwood Miami CEO Forum - Eagle-Tribune
Medicus Pharma to Present Drug Development Programs at Roth Conference - MyChesCo
MDCX Maintains Buy Rating with Stable Price Target | MDCX Stock News - GuruFocus
Small cap wrap: Medicus Pharma, C3 Metals, Protalix BioTherapeutics… - Proactive financial news
Medicus Pharma provides additional Phase 2 data for SkinJect Cancer therapy - Proactive financial news
Medicus Pharma Highlights Strong Phase 2 SkinJect Results in Basal Cell Carcinoma - TipRanks
Medicus says Phase 2 data supports further development of SkinJect therapy for skin cancer - Proactive financial news
Medicus Pharma Provides Interpretation of Positive Phase 2 SkinJect™ Dataset - The Manila Times
SkinJect cancer patch clears 3 in 4 lesions in trial, may spare surgery - Stock Titan
Aug Ideas: Can Medicus Pharma Ltd Equity Warrant disrupt its industryWeekly Market Outlook & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Medicus Pharma CEO discusses Phase 2 skin cancer resultsICYMI - Proactive financial news
Medicus Pharma Raises Equity Financing, Reduces Yorkville Debenture - TipRanks
Medicus Pharma Reports Phase 2 Results for Skin Cancer Patch - MyChesCo
Aug Intraday: Is Medicus Pharma Ltd Equity Warrant subject to activist investor interestWeekly Profit Recap & Low Drawdown Trading Techniques - baoquankhu1.vn
Small caps: Medicus Pharma, BioHarvest Sciences, Bit Digital, Nextech3D.ai… - Proactive financial news
Small cap wrap: Medicus Pharma, BioHarvest Sciences, Bit Digital, Nextech3D.ai… - Proactive Investors
Medicus Pharma Ltd Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance And 40% Histological Clearance (CR) At Day 57 In 200µg Cohort - marketscreener.com
Medicus Pharma reports positive phase 2 results for microneedle skin cancer treatment - Proactive financial news
MDCX Navigates Uncertain Waters Amid Recent Earnings and Market Trends - timothysykes.com
Medicus Pharma Stock Swings After Skin Cancer Treatment Results - Benzinga
Medicus Pharma reports positive Phase 2 results for microneedle treatment for basal cell carcinoma - Yahoo Finance
Medicus Pharma Posts Strong Phase 2 Data for Microneedle Basal Cell Carcinoma Therapy - TipRanks
Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort - Bitget
Microneedle skin cancer patch shows 73% clearance in Medicus trial - Stock Titan
New to The Street to Broadcast Executive Leadership Interviews Featuring Medicus Pharma Ltd. (NASDAQ:MDCX), CitroTech (NYSE:CITR), Vivos Therapeutics, Inc. (NASDAQ:VVOS), and Virtuix Holdings ($VTIX) on Bloomberg Television Tonight at 6:30 PM - ACCESS Newswire
MDCXMedicus Pharma on Bloomberg World - Revista ADVFN
Medicus Pharma Showcases SkinJect and Teverelix Strategy at Roth Conference - TipRanks
Medicus Pharma to present at Roth Conference - Proactive financial news
Medicus Pharma To Participate in the 38th Annual Roth Conference - The Manila Times
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform - Treasure Coast News
Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement - Ashland Times-Gazette
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - Daily Comet
MDCX PE Ratio & Valuation, Is MDCX Overvalued - Intellectia AI
Medicus Pharma Ltd. Provides Update on United Arab Emirates (UAE) SKNJCT-004 Phase 2 Clinical Study to Non-Invasively Treat Basal Cell Carcinoma of the Skin (BCC) - Montgomery Advertiser
Medicus Pharma to acquire Antev for $75M in share exchange transaction - MSN
MDCX Technical Analysis & Stock Price Forecast - Intellectia AI
Finanzdaten der Medicus Pharma Ltd-Aktie (MDCX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):